Abstract
Background Higher BMI in childhood is associated with emotional and behavioural problems, but these associations may not be causal. Results of previous genetic studies imply causal effects but may reflect influence of demography and the family environment.
Methods This study used data on 40,949 8-year-old children and their parents from the Norwegian Mother, Father and Child Cohort Study (MoBa) and Medical Birth Registry of Norway (MBRN). We investigated the impact of BMI on symptoms of depression, anxiety, and attention-deficit hyperactivity disorder (ADHD) at age 8. We applied within-family Mendelian randomization, which accounts for familial effects by controlling for parental genotype.
Results Within-family Mendelian randomization estimates using genetic variants associated with BMI in adults suggested that a child’s own BMI increased their depressive symptoms (per 5kg/m2 increase in BMI, beta=0.26 S.D., CI=-0.01,0.52, p=0.06) and ADHD symptoms (beta= 0.38 S.D., CI=0.09,0.63, p=0.009). These estimates also suggested maternal BMI, or related factors, may independently affect a child’s depressive symptoms (per 5kg/m2 increase in maternal BMI, beta=0.11 S.D., CI:0.02,0.09, p=0.01). However, within-family Mendelian randomization using genetic variants associated with retrospectively-reported childhood body size did not support an impact of BMI on these outcomes. There was little evidence from any estimate that the parents’ BMI affected the child’s ADHD symptoms, or that the child’s or parents’ BMI affected the child’s anxiety symptoms.
Conclusions We found inconsistent evidence that a child’s BMI affected their depressive and ADHD symptoms, and little evidence that a child’s BMI affected their anxiety symptoms. There was limited evidence of an influence of parents’ BMI. Genetic studies in samples of unrelated individuals, or using genetic variants associated with adult BMI, may have overestimated the causal effects of a child’s own BMI.
Funding This research was funded by the Health Foundation. It is part of the HARVEST collaboration, supported by the Research Council of Norway. Individual co-author funding: the European Research Council, the South-Eastern Norway Regional Health Authority, the Research Council of Norway, Helse Vest, the Novo Nordisk Foundation, the University of Bergen, the South-Eastern Norway Regional Health Authority, the Trond Mohn Foundation, the Western Norway Regional Health Authority, the Norwegian Diabetes Association, the UK Medical Research Council. The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit.
Competing Interest Statement
OAA has received speaker's honorarium from Sunovion and Lundbeck and is a consultant for HealthLytix.
Funding Statement
This research was funded by a project entitled Social and economic consequences of health: causal inference methods and longitudinal, intergenerational data, which is part of the Health Foundation's Social and Economic Value of Health Programme (Grant ID: 807293). The Health Foundation is an independent charity committed to bringing about better health and health care for people in the UK. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (#229624). Individual co-authors area also supported by specific sources of funding. ZA is supported by a Marie Skłodowska-Curie Fellowship from the European Union (894675) and the South-Eastern Norway Regional Health Authority (2019097). TR is supported by the Research Council of Norway (274611 PI: Reichborn-Kjennerud). OAA is funded by the Research Council of Norway (223273) and EU H2020 RIA (847776 CoMorMent). OH is supported by the University of Bergen, Norway. SJ was supported by Helse Vest's Open Research Grant (grants #912250 and F-12144), the Novo Nordisk Foundation (grant NNF19OC0057445) and the Research Council of Norway (grant #315599). PN is supported by the European Research Council (AdG SELECTionPREDISPOSED #293574), the Trond Mohn Foundation (Mohn Center for Diabetes Precision Medicine), the Research Council of Norway (FRIPRO grant #240413), the Western Norway Regional Health Authority (Strategic Fund: Personalized Medicine for Children and Adults), the Novo Nordisk Foundation (grant #54741), and the Norwegian Diabetes Association. AH was supported by the South-Eastern Norway Regional Health Authority (2018059, 2020022) and the Research Council of Norway (288083). LDH is supported by a Career Development Award from the UK Medical Research Council (MR/M020894/1). NMD was supported via a Research Council of Norway grant (295989). The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_00011/1] (AMH, ES, LDH, NMD, GDS, TM]. The funders had no role in the design or execution of this analysis, interpretation of results, or the decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and The Regional Committees (REC) for Medical and Health Research Ethics. The REC South East Norway, one of four in Norway, was the ethical committee that evaluated the ethics of this study. Approval from the REC was granted (2016/1702). Informed consent was obtained from each MoBa participant upon recruitment, which included consent to link to the Medical Birth Registry of Norway (MBRN). The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† joint senior authors
In the revision of 17/10/22 an older version of the abstract was incorrectly uploaded. Both the abstract and manuscript now relate to the latest version.
Data Availability
The consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to data sets for replication should submit an application to datatilgang{at}fhi.no. Access to data sets requires approval from The Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa.
